CAP-1002
Phase 2Biologic
CAP-1002 is one of 62 biologic programs targeting Duchenne Muscular Dystrophy. It is currently in Phase 2.
2
Indications
4
Total Trials
0
Active Trials
61
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1Spikevax
ModernaPreclinical
Stivarga
BayerPreclinical
Aimovig
AmgenPreclinical
Calciferol
Alnylam PharmaceuticalsPreclinical
Activella
Eli LillyPreclinical
CAP-1002
CCapricor Inc.
Phase 2
Tricor
JJagotec
Preclinical
Rayaldee
OOrganon and Co
Preclinical
Achromycin V
WWyeth-Lederle Vaccines
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
COVID-192 trials
Duchenne Muscular Dystrophy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CAP-1002. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- CCapricor Inc.